使用Freedom SOLO无支架生物瓣行主动脉瓣置换术:625例患者中期随访的临床与血流动力学表现
单中心回顾性观察研究纳入2009年5月至2017年5月在Sint-Jan医院使用Freedom Solo无支架瓣行主动脉瓣置换的625例患者,评估术后早期及中期临床与超声心动图结果。术后平均峰值压差14.3±8.14 mmHg,平均压差7.5±4.46 mmHg;7年总体生存率55%(95%CI 47-62),7年免于再手术94%(95%CI 88-97)。作者认为该瓣膜安全,中期耐久性良好。
要点
- 625例患者术后平均峰值压差14.3±8.14 mmHg,平均压差7.5±4.46 mmHg。
- 早期(30天)总死亡率为3.5%,孤立性主动脉瓣置换者为0.8%(n=2)。
- 7年总体生存率55%(95%CI 47-62),7年免于再手术94%(95%CI 88-97)。
核心结论
- 作者认为Freedom Solo无支架主动脉瓣安全,临床与血流动力学结果优良,结构性瓣膜衰败与再次置换少见,中期耐久性良好。
研究设计与样本
- 单中心回顾性观察性研究,回顾性收集2009年5月至2017年5月在Sint-Jan医院使用Freedom Solo无支架瓣(LivaNova,伦敦,英国)行主动脉瓣置换的625例患者的临床与超声心动图数据。
主要发现
- 患者平均年龄76±6.9岁,早期(30天)总死亡率为3.5%,孤立性主动脉瓣置换者早期死亡率为0.8%(n=2)。
- 早期再干预率为3%(n=19),永久起搏器植入率为3%。
- 术后平均峰值压差为14.3±8.14 mmHg,平均压差为7.5±4.46 mmHg。
- 14例患者行瓣膜取出,其中2例因结构性瓣膜衰败、8例因心内膜炎。
- 7年总体生存率为55%(95%CI 47-62),7年总体免于再手术率为94%(95%CI 88-97),免于因心内膜炎手术率为97%(95%CI 94-99),免于因结构性瓣膜衰败手术率为98%(95%CI 90-99)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our goal was to analyse the haemodynamic and clinical results after implantation of the Freedom SOLO stentless aortic valve replacement by assessing the immediate postoperative results regarding mortality, discharge echocardiographic gradients and reoperation rates and by evaluating these results in the medium term. METHODS: This study was designed as a single-centre retrospective observational trial. Clinical and echocardiographic data were collected retrospectively from 625 patients undergoing an aortic valve replacement using the Freedom Solo stentless valve (LivaNova, London, UK) at the Sint-Jan Hospital, Bruges, between May 2009 and May 2017. RESULTS: The mean age of the patient was 76 ± 6.9 years. Early operative (30-day) mortality was 3.5% overall and 0.8% (n = 2) in patients having isolated aortic valve replacement. Early reinterventions were necessary in 3% of patients (n = 19). Permanent pacemaker implantation was performed in 3%. The mean postoperative peak gradient was 14.3 ± 8.14 mmHg, and the mean gradient was 7.5 ± 4.46 mmHg. Fourteen patients underwent explantation, 2 of which were for structural valve deterioration and 8 for endocarditis. Overall survival at 7 years was 55% [95% confidence interval (CI) 47-62]. At 7 years, freedom from reoperation overall, freedom from operation for endocarditis and freedom from operation for structural valve deterioration were 94% (95% CI 88-97), 97% (95% CI 94-99) and 98% (95% CI 90-99), respectively. CONCLUSIONS: The Freedom Solo stentless aortic valve has proved to be safe, with excellent clinical and haemodynamic results. Structural valve degeneration and explantation occur infrequently, illustrating good durability in the medium term.
引用
- Fleerakkers J, Schepens M, Ranschaert W, et al. Aortic valve replacement using the Freedom SOLO stentless bioprosthesis: clinical and haemodynamic performance in 625 patients at medium-term follow-up. Eur J Cardiothorac Surg. 2018. PMID: 29846555. doi:10.1093/ejcts/ezy202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。